Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Other Net Income (Loss) : ¥-0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co Other Net Income (Loss)?

Anhui Wanbang Pharmaceutical Technology Co's Other Net Income (Loss) for the three months ended in Mar. 2024 was ¥0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0.0 Mil.

Anhui Wanbang Pharmaceutical Technology Co's quarterly Other Net Income (Loss) declined from Sep. 2023 (¥0.0 Mil) to Dec. 2023 (¥-0.0 Mil) but then increased from Dec. 2023 (¥-0.0 Mil) to Mar. 2024 (¥0.0 Mil).

Anhui Wanbang Pharmaceutical Technology Co's annual Other Net Income (Loss) increased from Dec. 2021 (¥-0.0 Mil) to Dec. 2022 (¥-0.0 Mil) and increased from Dec. 2022 (¥-0.0 Mil) to Dec. 2023 (¥0.0 Mil).

Anhui Wanbang Pharmaceutical Technology Co Other Net Income (Loss) Historical Data

The historical data trend for Anhui Wanbang Pharmaceutical Technology Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anhui Wanbang Pharmaceutical Technology Co Other Net Income (Loss) Chart

Anhui Wanbang Pharmaceutical Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Anhui Wanbang Pharmaceutical Technology Co Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial									-	-	-	-	-

Anhui Wanbang Pharmaceutical Technology Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.0 Mil.

Anhui Wanbang Pharmaceutical Technology Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » Other Net Income (Loss)

Traded in Other Exchanges

N/A

Address

southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000

Website

http://www.ahwbyy.cn

Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines